- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.05. | Xilio Therapeutics reports Q1 results | 1 | Seeking Alpha | ||
| 12.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 455 | GlobeNewswire (Europe) | On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data... ► Artikel lesen | |
| 12.05. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 | 1 | GlobeNewswire (USA) | ||
| 16.04. | Xilio Therapeutics appoints Cheryl Blanchard to board | 1 | Investing.com | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.04. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 23.03. | Xilio plans mid-2026 IND filing for cancer therapy XTX501 | 2 | Investing.com | ||
| 23.03. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 23.03. | Xilio plant IND-Antrag für Krebstherapie XTX501 für Mitte 2026 | 2 | Investing.com Deutsch | ||
| 23.03. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 23.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results | 378 | GlobeNewswire (Europe) | XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class... ► Artikel lesen | |
| 23.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 17.03. | Xilio Therapeutics to present data on masked cancer therapy at AACR | 2 | Investing.com | ||
| 17.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.03. | Xilio Therapeutics implements 1-for-14 reverse stock split | 4 | Investing.com | ||
| 12.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces 1-for-14 Reverse Stock Split | 296 | GlobeNewswire (Europe) | WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 25,050 | -0,04 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,470 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| ERASCA | 13,170 | -0,08 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| IMMUNOVANT | 31,110 | -0,13 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data | ||
| SUMMIT THERAPEUTICS | 15,075 | +0,03 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| EDGEWISE THERAPEUTICS | 36,180 | -0,08 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| ABSCI | 5,935 | -0,08 % | BTIG initiates Absci stock with buy rating on AI drug platform | ||
| VERA THERAPEUTICS | 31,250 | -0,06 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,990 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen | |
| IMMUNOME | 19,820 | +0,05 % | Immunome: Phase-3-Studie zu Varegacestat zeigt hohe Wirksamkeit bei Desmoid-Tumoren | ||
| ADMA BIOLOGICS | 7,770 | +0,13 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 15,470 | -0,06 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 58,76 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,690 | 0,00 % | Tyra Biosciences, Inc. - 8-K, Current Report | ||
| PHATHOM PHARMACEUTICALS | 10,090 | 0,00 % | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | ~1.35 million total VOQUEZNA prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,68 % bei einem Aktienkurs von 8,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.